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Intramembrane proteolysis is now widely recognized as an
important physiological pathway required for reverse signaling
and membrane protein degradation. Aspartyl intramembrane
cleaving proteases of the GXGD-type play an important regula-
tory role in health and disease. Besides -secretase/presenilin,
signal peptide peptidase (SPP) and SPP-like (SPPL) peptidases
also belong to the family of GXGD-type aspartyl proteases.
Although recently the first SPPL2a/b substrates have been iden-
tified, very little is known about substrate requirements, which
allow them to be efficiently processedwithin themembrane.We
demonstrate that similar to -secretase substrates, intramem-
brane proteolysis of Bri2 (Itm2b) is greatly facilitated by an ini-
tial shedding event mediated by ADAM-10. Serial deletions
revealed that the length of the ectodomain negatively correlates
with efficient intramembrane proteolysis. Bri3 (Itm2c), which is
highly homologous to Bri2, fails to be shed. Failure of shedding
of Bri3 is accompanied by a lack of intramembrane proteolysis
by SPPL2b. Surprisingly, a low molecular weight membrane-
retained stub of Bri3 also fails to be processed by SPPL2b, indi-
cating that shedding per se is not sufficient for subsequent
intramembrane proteolysis. Extensive domain swapping analy-
sis reveals that primary sequence determinants within the intra-
cellular domain and the transmembrane domain together with
short luminal juxtamembrane sequences are required for effi-
cient intramembrane proteolysis.
Signal peptide peptidase (SPP)4 (1), its homologues, the SPP-
like peptidases (SPPL) SPPL2a, b, and c and SPPL3 (2, 3) as well
as the Alzheimer’s disease-associated presenilins (PS1 or PS2)
are intramembrane-cleaving proteases (ICLiPs) of the GXGD-
type aspartyl protease family (4, 5). GXGD designates a novel
active sitemotif locatedwithin transmembrane domain (TMD)
7 of all known intramembrane-cleaving aspartyl proteases (6).
The GXGDmotif contains one of the two critical aspartyl resi-
dues conserved in all GXGD-type proteases. The second aspar-
tyl residue is part of a conserved YD motif located in TMD 6.
Both motifs share no homologies with conventional aspartyl
proteases (6). SPP/SPPLs and PSs only share very limited
sequence homologies (2); however, besides the YD and GXGD
domain, a third more C-terminal PAL sequence is conserved
among all members of the GXGD proteases (2). Recently it has
been shown that the PALmotif may not only present a binding
site for transition state inhibitors of -secretase and SPP (7),
but, at least in the case of PS1,may interact with theN-terminal
critical aspartate located within TMD 6 (8, 9). In line with data
from electron microscopy (10, 11) and cysteine scanning
mutagenesis (12, 13), these findings suggest awater-filled cavity
harboring the catalytic center of -secretase. For SPP/SPPL
family members, no such analyses have been performed yet;
therefore it is too early to speculate whether similar structural
features as observed for PS1 also apply. Although SPP/SPPLs
apparently exert protease function in the absence of additional
essential co-factors (1, 14, 15) and can even be functionally
expressed in bacteria (16), -secretase is a protease complex
composed of PS and three additional proteins, Nicastrin
(NCT), APH-1 (APH-1a L/S or APH-1b), and PEN-2 (17). All
four proteins are necessary and sufficient for authentic -secre-
tase function (18). PS harbors the active site aspartyl residues
and the interacting PAL motif, whereas NCT is discussed as a
substrate receptor (19), and PEN-2 is discussed as a stabilizing
factor keeping the auto-proteolytically generated PS fragments
in close contact (20, 21). No function has so far been assigned to
APH-1.
SPP was discovered as an ICLiP responsible for removing
hydrophobic signal peptides liberated from the N terminus of
secreted or transmembrane proteins by signal peptidase (SP)
cleavage during their co-translocation into the endoplasmic
reticulum (1). In addition to signal peptide degradation, SPP is
also required for the generation of cell surface histocompatibil-
ity antigen-E epitopes and processing of the hepatitis C virus
polyprotein (5). A data base search for SPP homologues
revealed SPPL2a, b, and c and SPPL3 (2, 3). Currently, little is
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known about the function of SPPL family members. No physi-
ological substrates are known for SPPL3 and SPPL2c. In con-
trast, three substrates have been identified to be processed by
SPPL2a/b. These include tumor necrosis factor  (14, 22), the
Fas ligand (FasL) (23), and Bri2 (Itm2b) (24). In the case of
tumor necrosis factor , reverse signaling has been observed
upon liberation of the intracellular domain (ICD) by SPPL2a
and SPPL2b (22). The tumor necrosis factor  ICD regulates
expression of interleukin-12 probably via nuclear signaling
(22). Similarly, the ICD of FasL negatively regulates gene
transcription (23). Consistent with its predominant function in
signal peptide removal, SPP is located within the endoplasmic
reticulum (15, 22) and probably retained by a KKXX retention
signal. SPPL3 (15) and SPPL2c (22) are also located within the
endoplasmic reticulum, and it is tempting to speculate that they
are involved in signal peptide removal like SPP. In contrast,
SPPL2a and SPPL2b occur throughout the secretory pathway
including the plasma membrane and endosomes/lysosomes
(15). This suggests that the differential subcellular localization
of SPPL proteases restricts the number of available substrates.
In contrast to-secretase, which only accepts type 1 transmem-
brane proteins as substrates for intramembrane proteolysis (17,
25), all currently known SPP/SPPL substrates are in type 2 ori-
entation (1, 5, 14, 22–24). For -secretase and other ICLiPs, it
has been shown that intramembrane proteolysis strictly follows
a previous ectodomain shedding event. Shedding removes the
bulk of the ectodomain and leaves behind a small membrane-
retained stub. In the case of -secretase, substrates with an
ectodomain shorter than 50 amino acids are preferentially
processed (26). Moreover, only pre-shed substrates bind to
-secretase (27), whereas full-length proteins are most likely
not recognized. Substrate recognition via its free N terminus is
apparently mediated by NCT through a conserved glutamate
residue (19), although this finding has recently been challenged
(28). SPP may also require precleavage of its substrate by SP (1,
29); however, even uponmutagenesis of the SP recognition site,
some residual intramembrane proteolysis still occurs (29). In
line with the possibility that full-length substrates may be
cleaved at least to some extent, SPPL2b was shown to co-im-
munoprecipitate both the truncated substrate and the full-
length precursor (14, 24). However, the fact that substantially
more full-length protein co-immunoprecipitates with the
active SPPL2b protein as compared with the truncated frag-
ment suggested that the lattermay be preferentially turned over
by intramembrane proteolysis (14, 24). It is also not known
whether primary sequences within the TMD or adjacent
domains of SPPL2b substrates are critical for substrate recog-
nition and turnover.
Bri3 as well as Bri2, which is genetically associated with
Familial British and Danish dementia, belong to the family of
highly homologous Bri proteins (30). We demonstrate that,
although very homologous to Bri2, Bri3 is not a substrate for
regulated intramembrane proteolysis. This finding allowed us
to study intramembrane proteolysis independent of ectodo-
main shedding. We demonstrate that shedding greatly facili-
tates subsequent intramembrane proteolysis. However, trunca-
tion of the ectodomain of a potential SPPL2b substrate is
surprisingly not sufficient to allow intramembrane proteolysis,
because in addition to removal of the bulk of the ectodomain,
sequence determinants within the ICD, the TMD, and the
luminal juxtamembrane domain (JMD) are also required.
EXPERIMENTAL PROCEDURES
Cell Culture, cDNAs, and Transfection—HEK-293EBNA
(HEK-293) were cultured in Dulbecco’s modified Eagle’s
medium with Glutamax (Invitrogen) supplemented with 10%
fetal calf serum (Invitrogen) and 1% penicillin/streptomycin
(Invitrogen). HEK-293 single cell clones stably expressing
SPPL2b or SPPL2b D421A containing a C-terminal hemagglu-
tinin tag (AYPYDVPDYA) have been described before (24).
Bri2 and Bri3 cDNAs were purchased from Deutsches Ressou-
rcezentrum für Genomforschung (Berlin, Germany). cDNAs
encoding chimeric proteins (Table 1) were generated by PCR.
For all constructs the propetide at theC terminuswas removed,
and a N-terminal FLAG tag (DYKDDDDK) as well as a C-ter-
minal V5 tag (GKPIPNPLLGLDST) was added. Sequences of
the oligonucleotides used for PCR are available upon request.
PCRproductswere subcloned into theHindIII andXbaI sites of
pcDNA6.0-V5-His A (Invitrogen). All of the cDNA constructs
were verified by sequencing. Transient transfection of HEK-
293 cell lines stably expressing the indicated SPPL2b variants
was carried out using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s instructions. The bovine ADAM-10
wt and ADAM-10 E384A constructs are a generous gift from
Dr. Rolf Postina.
Antibodies, Immunoprecipitation, and Immunoblotting—
The monoclonal anti-FLAGM2 and the polyclonal hemagglu-
tinin 6908 antibody were obtained from Sigma; the poly- and
monoclonal V5 antibodies were purchased from Chemicon
(Schwalbach, Germany) and Invitrogen, respectively. The poly-
clonal antibodies against ADAM-10 and calnexin were pur-
chased from Calbiochem and Stressgene/Biomol (Hamburg,
Germany). The monoclonal anti-Giantin antibody (ALX-804–
600) was obtained from Alexa (AXXORADeutschland GmbH,
Lörach,Germany). 22C11 antibody recognizing theN terminus
of APP was purchased from Chemicon (Schwalbach, Ger-
many). Anti-mouse and anti-rabbit secondary antibodies were
purchased from Promega (Madison, WI). Immunoprecipita-
tion assays, gel electrophoresis, immunoblotting experi-
TABLE 1
Generation of chimeric Bri variants and deletions
The numbers represent the corresponding amino acids of Bri2 and Bri3,
respectively.
Construct ICD TMD Ectodomain
Bri2 Bri2 1–54 Bri2 55–75 Bri2 76–237
Bri3 Bri3 1–54 Bri3 55–75 Bri3 76–233
Bri2E Bri2 1–54 Bri2 55–75 Bri2 76–98
Bri3E Bri3 1–54 Bri3 55–75 Bri3 76–98
Bri2/3 Bri2 1–54 Bri2 55–75 Bri3 76–233
Bri2/3 - 0 Bri2 1–54 Bri2 55–75
Bri2/3 - 10 Bri2 1–54 Bri2 55–75 Bri3 76–86
Bri2/3 - 23 Bri2 1–54 Bri2 55–75 Bri3 76–98
Bri2/3 - 59 Bri2 1–54 Bri2 55–75 Bri3 76–134
Bri2/3 - 91 Bri2 1–54 Bri2 55–75 Bri3 76–166
Bri2/3 - 124 Bri2 1–54 Bri2 55–75 Bri3 76–199
Bri2/3 - 156 Bri2 1–54 Bri2 55–75 Bri3 76–233
Bri2/3E Bri2 1–54 Bri2 55–75 Bri3 76–98
Bri3/2/2 Bri3 1–54 Bri2 55–75 Bri2 76–237
Bri2Ins Bri3 45–54 Bri2 1–44, Bri3 45–54 Bri2 55–75 Bri2 76–237
Bri2/3/2 Bri2 1–54 Bri3 55–75 Bri2 76–237
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ments, and assays were carried out as described previously
(14, 15).
Immunocytochemistry andConfocal Imaging—The indicated
cell lines were grown on polylysine-coated glass coverslips to
60–80% confluence and processed for immunofluorescence as
described before (15). Cells were treated with 0.1% Triton to
perform co-staining with the Golgi marker giantin or were left
untreated to perform surface stainings. Confocal images were
obtained with Zeiss 510Meta confocal laser scanning micro-
scope system equipped with a 100/1.3 objective described pre-
viously (31). The images were assembled and processed using
Adobe Illustrator.
Inhibitor Treatment and Quantification—To inhibit
SPPL2b, the cells were treated overnight with a final concentra-
tion of 30 M (Z-LL)2-ketone (Calbiochem), a known SPP/
SPPL inhibitor (32). For quantification, the proteins were
immunoblotted as described above and detected using the
enhanced chemiluminescence technique (GE Healthcare). The
chemiluminescence signals of at least three independent exper-
imentsweremeasuredwith aCDcamera-based imaging system
(Alpha Innotec). Statistical significance was determined with
Student’s t test. Statistical significant p values 0.05, 0.005,
and 0.0005 are represented by *, **, and ***, respectively.
Alignment and Sequence Analysis—Bri2 and Bri3 protein
sequenceswere aligned usingVectorNTI 9 (Invitrogen). Amino
acid identity and similarity were calculated using EMBOSS
pairwise alignment algorithms.
RESULTS
Differential Shedding of Bri2 and Bri3—Although substrate
requirements for -secretase (Ref. 26; summarized in Refs. 17
and 33) and SPP (29) are at least partially described, very little is
known about determinants that allow SPPLs to recognize their
appropriate protein substrates. Therefore we specifically
searched for substrate requirements of SPPL2b, an ICLiP of the
GXGD-type located within the late secretory compartments
including plasma membrane and endosomes, because this may
allow a direct comparison of the properties of -secretase with
those of the SPPLs. Recentlywe and others have identified three
substrates, tumor necrosis factor  (14, 22), Bri2 (24), and the
FasL (23), for intramembrane proteolysis by SPPL2a/b.Wenow
compared the processing of two homologous Bri proteins, Bri2
and Bri3 (30, 34) (Fig. 1A). cDNAs encoding the Bri2 or the Bri3
proteinwere transfected intoHEK-293 cell lines stably express-
ing either wt SPPL2b or the functional inactive SPPL2b D/A
(15) mutant. As described previously (24), the BRICHOS
domain was efficiently shed upon transfection of Bri2 (Fig. 1B).
Shedding occurred independent of the expression ofwt SPPL2b
or nonfunctional SPPL2b D/A. As expected, we also detected
the Bri2 N-terminal fragment (Bri2 NTF) generated by the
shedding event within the cell lysate (Fig. 1B). As observed
before (24), the shedding event appeared to be heterogeneous
because multiple NTFs of slightly different molecular weight
are detected. The Bri2 ICD was efficiently generated upon co-
expression of the proteolytically active SPPL2b (Fig. 1B). In
contrast, upon expression of the inactive SPPL2 D/A variant,
the Bri2NTF accumulated, andnoBri2 ICDwas generated (Fig.
1B) (24). Interestingly, when we expressed the homologous
Bri3, no secretion of the Bri3 BRICHOS domain was observed
(Fig. 1B). This is in line with previous findings that also sug-
gested that Bri3 fails to undergo shedding (35). Intramembrane
proteolysis by SPPL2b was also not observed, as shown by the
lack of detectable Bri3 ICD even after long exposure (Fig. 1B).
This suggests that although Bri2 and Bri3 share substantial
sequence similarities throughout their ectodomains (Fig. 1A),
the shedding protease discriminates between these similar sub-
strates. However, another possibility would be that Bri2 and
Bri3 are differentially targeted and Bri3 does not reach shed-
dase/SPPL2b containing cellular compartments. To prove this
possibility, we investigated the subcellular distribution of Bri2
and Bri3 by immunohistochemistry. This revealed that both
Bri2 and Bri3 are similarly targeted through the secretory path-
way and occurwithin giantin-positiveGolgi compartments and
on the plasma membrane (Fig. 1C), and thus both co-localize
with SPPL2b (24). From these experiments we conclude that
Bri3, although it is quite homologous to Bri2 and occurs within
the same subcellular compartments, fails to undergo shedding
as well as intramembrane proteolysis.
Ectodomain Shedding Is Not Sufficient for Intramembrane
Proteolysis—In line with data obtained for substrate require-
ments of -secretase (26), we postulated that Bri2 and Bri3 vari-
ants lacking large parts of their ectodomainsmay allow efficient
intramembrane proteolysis. We therefore generated Bri2 and
Bri3 variants lacking almost the entire ectodomain (Bri2E and
Bri3E). Upon co-expression with SPPL2b, Bri2E underwent
intramembrane proteolysis and allowed production of robust
levels of the Bri2 ICD (Fig. 2A (24)). The Bri2 ICD was not
generated upon treatment with the SPPL2b inhibitor (Z-LL)2-
ketone as expected (Fig. 2A) (24). Surprisingly, when we
expressed Bri3E, no intramembrane proteolysis was detecta-
ble (Fig. 2A), although the ectodomain should have been suffi-
ciently truncated to allow constitutive intramembrane proteol-
ysis independent of a previous shedding event. This suggests
that intramembrane proteolysis may occur only to a very lim-
ited level, which, however, is beyond the detection limit for the
Bri3 ICD. From these findings we conclude that shedding per se
is not sufficient to allow constitutive intramembrane proteol-
ysis. Therefore, sequence elements within the small NTF
of SPPL2b substrates are additionally required to trigger
intramembrane proteolysis. To further pursue the influence of
ectodomain shedding on SPPL2b-dependent intramembrane
proteolysis, we generated a cDNAconstruct encoding a Bri var-
iant containing the Bri2 ICD and TMD fused to the Bri3
ectodomain (Bri2/3; Fig. 2B). This variant was expressed in
HEK-293 cells together with wt SPPL2b or the nonfunctional
SPPL2b D/A. Upon expression of Bri2/3, no shedding was
detected (Fig. 2B and supplemental Fig. S1), confirming again
that Bri2 and Bri3 are differentially processed within their
ectodomain. Differential targeting of Bri2/3 was excluded,
because this chimeric variant is observed throughout the secre-
tory pathway, including a giantin-positive Golgi compartment
and the plasma membrane (Fig. 2C). Surprisingly, although no
shedding occurs as monitored by the lack of the NTF in the cell
lysate and the BRICHOS domain in the conditioned medium,
SPPL2b-dependent ICD generation was observed to some
extent (Fig. 2B). It should be noted, however, that ICD genera-
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tion of Bri2/3 was substantially lower as compared with wt Bri2
(Fig. 2B). Taken together these findings indicate that shedding
facilitates intramembrane proteolysis but is not absolutely
required for ICD generation.
Shedding by ADAM-10 Facili-
tates Intramembrane Proteolysis—
To further confirm that shedding
facilitates intramembrane proteoly-
sis of a natural substrate, we co-ex-
pressed ADAM-10, the major shed-
dase known to process Bri2 (24), or
its catalytically inactive variant
ADAM-10 E384A (36) with wt Bri2
and SPPL2b. Enhanced expression
of wt ADAM-10 results in elevated
levels of the Bri2 NTF in the cell
lysate and BRICHOS in the condi-
tioned media, respectively (Fig. 3).
Moreover, elevation of shedding
caused enhanced ICD generation
(Fig. 3), demonstrating that shed-
ding indeed facilitates subsequent
intramembrane proteolysis. To fur-
ther prove this hypothesis, we com-
pared intramembrane proteolysis of
full-length Bri2 and Bri2E. In line
with the finding that shedding
is a rate-limiting step, Bri2E is
more efficiently endoproteolyzed by
SPPL2b than the full-length protein
(data not shown).
Intramembrane Proteolysis Nega-
tively Correlates with the Size of the
Ectodomain—A size-selecting mech-
anism is known as a key step in sub-
strate recognition by -secretase.
Here the appropriately truncated
substrate is apparently identified by
NCT (19), and substrates with
ectodomains smaller than 50 amino
acids are preferentially processed
(26). However, in the absence of
NCT, no such mechanisms would
be expected for SPPL2b, although,
surprisingly, we observed that
shedding facilitates subsequent
intramembrane proteolysis. This
may indeed suggest a size-selecting
mechanism similar to that reported
for-secretase.We therefore gener-
ated fusion proteins of the Bri2 ICD
and TMD with Bri3 ectodomains of
increasing length (Fig. 4A). This
strategy allowed us to investigate
whether there is a size selecting
process, because the Bri3 ectodo-
main does not allow shedding (Fig.
1B). Surprisingly, we found a strong
negative correlation of ICD generation with the size of the
ectodomain (Fig. 4, B and C). Substantial ICD production was
observed only upon expression of substrates with less than 59
amino acids in their ectodomain. Most efficient intramem-
FIGURE 1. The Bri2 homologue Bri3 is not a substrate for regulated intramembrane proteolysis by SPPL2b.
A, amino acid sequence alignment of Bri2 and Bri3. The Furin cleavage site and the transmembrane domain are
shown in bold, and identical residues are highlighted in gray. Sequence identity and similarity are 43 and 60%,
respectively. B, Bri3 neither undergoes ectodomain shedding nor intramembrane proteolysis by SPPL2b. Upon
co-expression of SPPL2b with Bri2 or Bri3 in HEK-293 cells, NTF and ICD generation are observed only for Bri2. Note
that Bri2 ICD generation is abolished upon co-expression of the catalytic inactive SPPL2b D/A mutant. The soluble
ectodomain (BRICHOS) in conditioned medium is detected for Bri2, but not for Bri3 expressing cells. Full-length Bri
as well as the NTFs and ICDs were detected using the anti-FLAG antibody. The corresponding BRICHOS domains
were visualized with an anti-V5 antibody. Reprobing for soluble APP with 22C11 antibody shows that ectodomain
shedding in general is not affected upon expression of Bri3. The expression levels of SPPL2b were similar in Bri2/Bri3
expressing cells (data not shown).  indicates longer blot exposure. C, Bri3 is present in late secretory compart-
ments. Immunohistochemistry of HEK-293 cells transfected with Bri3 reveals localization at the plasma membrane
(stainings without Triton X-100) as well as co-localization with the Golgi compartment marker giantin (stainings with
Triton X-100). Bri2 and Bri3 were detected using the anti-V5 antibody. The localization of Bri3 and Bri2 is similar. The
scale bar represents 10 m.
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brane proteolysis occurred with
substrates having less than 23 lumi-
nal amino acids (Fig. 4, B and C),
which is surprisingly similar to find-
ings made with -secretase sub-
strates (26).
Sequence Determinants in All
Three Subdomains of the Bri2 NTF
Are Required for Intramembrane
Proteolysis—The results shownabove
suggest that in addition to a size selec-
tion mechanism, sequence determi-
nants within theNTF of the substrate
must also influence SPPL2b cleav-
age efficiency, because ectodomain
truncation of Bri3 is not sufficient to
convert Bri3 into a SPPL2b sub-
strate (Fig. 2A). Therefore, we first
investigated the influence of the
luminal JMD on intramembrane
proteolysis. We generated Bri E
constructs that contained 23 amino
acids of the luminal domain of
either Bri2 or Bri3 fused to theTMD
and ICD of Bri2 (Bri2E and Bri2/
3E; Fig. 5A) and directly compared
the efficiency of SPPL2b-dependent
intramembrane proteolysis. This re-
vealed that Bri2/3E is turned over
with70% less efficiency compared
with Bri2E (Fig. 5,B andC). This is
reflected not only by a significant
reduction of ICD formation but also
by a lack of substrate accumulation
upon expression of the nonfunc-
tional SPPL2b D/A mutant (Fig.
5B). Thus the luminal 23 amino acid
JMD of Bri2 contributes important
determinants required for SPPL2b-
dependent cleavage.
We next investigated whether
the ICD also contributes to intra-
membrane proteolysis. To do so
we fused the Bri3 ICD to the TMD
and ectodomain of Bri2, creating
Bri3/2/2 (Fig. 6A). Expression of
Bri3/2/2 revealed about 60% less
ICD generation compared with
that from the wt Bri2 (Fig. 6, B and
C). This suggests that sequences
within the ICD influence intramem-
brane proteolysis by SPPL2b. To
further map the sequence require-
ments within the cytoplasmic tail,
we inserted 10 amino acids of
the Bri3 cytosolic juxtamembrane
domain into the Bri2 ICD creat-
ing Bri2Ins Bri3 45–54 (Fig. 6D).
FIGURE 2. Influence of ectodomain shedding on SPPL2b-dependent intramembrane proteolysis.
A, shedding per se is not sufficient for SPPL2b-dependent intramembrane proteolysis. Co-expression of
SPPL2b with Bri2 or Bri3 mutants lacking the BRICHOS ectodomain (Bri2E or Bri3E) in HEK-293 cells
allows SPPL2b-dependent ICD generation for Bri2. Bri2E and Bri3E were detected using the anti-FLAG
antibody. Treatment with (Z-LL)2-ketone inhibits Bri2 ICD generation. Bri3E is not processed by SPPL2b.
B, ectodomain shedding is not a prerequisite for SPPL2b-dependent intramembrane proteolysis. Upon
co-expression of Bri2/3 with SPPL2b, both BRICHOS in the conditioned media and NTF in cell lysates are
not detected. For detection of full-length Bri2, Bri2/3, or N-terminal processing products an anti-FLAG
antibody was used. The corresponding BRICHOS domains were visualized with an anti-V5 antibody. Bri2/3
does not undergo ectodomain shedding. However, note that low amounts of ICD are generated in a
SPPL2b-dependent manner. The remaining Bri2 ICD derived from wt Bri2 upon expression of the nonfunc-
tional D/A SPPL2b mutant is most likely caused by a low level expression of endogenous SPPL2b. Asterisks
indicate IP antibody cross-reaction,  indicates longer blot exposure. C, Bri2/3 is transported to late
secretory compartments. Immunohistochemistry of HEK-293 cells transfected with Bri2/3 reveals local-
ization at the plasma membrane (stainings without Triton X-100) as well as co-localization with the Golgi
compartment marker giantin (stainings with Triton X-100). Bri2 and Bri2/3 were detected using an anti-V5
antibody. The localization of Bri2 and Bri2/3 is similar. The scale bar represents 10 m.
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Expression of Bri2Ins Bri3 45–54 revealed an 60% reduction of
ICD formation (Fig. 6, E and F) very similar to the reduced
intramembrane proteolysis upon expression of Bri3/2/2 (Fig. 6,
B and C). Thus it is likely that the 10 amino acids of the jux-
tamembrane domain immediately beyond themembrane play a
major role for substrate recognition.
The above-described experiments (Fig. 2A) suggest that the
TMD may also be important for subsequent intramembrane
proteolysis, because the Bri2/3 variant allowed at least some
intramembrane proteolysis, whereas Bri3E failed to undergo
cleavage by SPPL2b (Fig. 2A). To further support this hypoth-
esis, we replaced theTMDof Bri2 by that of Bri3, generating the
Bri2/3/2 variant (Fig. 7A). Bri2 and Bri2/3/2 were expressed
with SPPL2b inHEK-293 cells. Substantial amounts of Bri2 ICD
were generated from wt Bri2 as expected (Fig. 7B). However,
upon expression of Bri2/3/2, we observed an 80% reduction
of ICD formation (Fig. 7, B and C). This suggests that, in addi-
tion to the luminal JMD and the ICD, the TMD of Bri2 also
provides very important sequence determinants.
DISCUSSION
Intramembrane proteolysis is becoming an increasingly
important cellular mechanism involved in numerous signaling
pathways as well as in protein degradation. Furthermore, some
of these proteases such as -secretase are major players in
abundant diseases, including Alzheimer disease. -Secretase
togetherwith SPP and the SPPLs represent the currently known
eukaryotic GXGD-type aspartyl proteases.We have now inves-
tigated the substrate requirements of SPPL2b. As described
above, SPPL2b, like the othermembers of the SPP/SPPL family,
does not require additional co-factors for activity like -secre-
tase. We therefore expected that SPPL2b may have some fun-
damentally different substrate requirements as compared with
-secretase. For example, one would have expected that
SPPL2b may not depend on trimming of its substrates by
shedding, because a size-selecting substrate receptor like
NCT is not required, and SPPL2a and SPPL2b are biologi-
cally active on their own (14, 15, 22–24). Surprisingly, we
found some substantial similarities in substrate selection of
-secretase and SPPL2b. Clearly, SPPL2b-mediated endo-
proteolysis is greatly facilitated by previous shedding of the
ectodomain of the substrate. In line with this notion,
intramembrane proteolysis by SPPL2b is enhanced by
expression of ADAM-10, the major Bri2 cleaving sheddase,
or by sequentially truncating the ectodomain of the sub-
strate. Very similar to -secretase, which only efficiently
FIGURE 3. Ectodomain shedding facilitates intramembrane proteolysis.
ADAM-10 enhances SPPL2b-dependent intramembrane proteolysis. Co-ex-
pression of Bri2 with wt ADAM-10, but not with the inactive E384A ADAM-10
mutant in HEK-293 cells, leads to increased amount of NTF in cell lysates and
BRICHOS secretion into the conditioned medium. Bri2 and its N-terminal
processing products were detected using an anti-FLAG antibody. The corre-
sponding BRICHOS domain was visualized with an anti-V5 antibody. ICD lev-
els are increased in cells expressing wt ADAM-10, showing that ectodomain
shedding facilitates SPPL2b-dependent intramembrane proteolysis. The
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FIGURE 4. Intramembrane proteolysis negatively correlates with the size
of the ectodomain. A, model of the Bri2/3 fusion proteins. All constructs
contain the ICD and the TMD of Bri2 but contain increasing parts of the Bri3
luminal domain. B, a short luminal domain of the substrate increases SPPL2b
cleavage efficiency. HEK-293 cells stably expressing SPPL2b were transfected
with the Bri2/3 fusion constructs shown in A. All fusion proteins were
detected using an anti-FLAG antibody. Robust generation of ICD is observed
only for the two shortest constructs (none or 10 luminal Bri3 residues).
Increasing the size of the luminal domain leads to decreased amounts of
ICD.  indicates longer blot exposure. C, quantitative analysis of experiment
shown in B. The data represent the means  S.D. of nine independent exper-
iments. The relative signal intensity of ICD compared with full-length protein
was measured for each construct, normalized to calnexin, and set to 100% for
the shortest construct. The addition of 10 luminal Bri3 residues to the shortest
construct leads to a 45% decrease in SPPL2b-dependent cleavage efficiency
(p  0.00009). Increasing the length of the luminal domain further reduces
the amount of ICD.
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processes substrates with an ectodomain smaller than 50
amino acids (26), SPPL2b-mediated cleavage is more effi-
cient the shorter the ectodomain is. Even the preferred size
of the ectodomain is similar for SPPL2b and -secretase (26).
However, the size of the ectodomain is an important, but not
exclusive, determinant for a SPPL2b substrate. This is rather
surprising, because SPPL2b does not interact with a NCT-
like protein, which could serve as a substrate receptor and
size selector. This raises the question of whether a domain
within SPPL2b itself could mediate substrate selection. The
only domains that may protrude into the luminal space could
be the hydrophilic loop between TMD 6 and TMD 7 and the
N-terminal domain of SPPL2b. The N-terminal domain
prior to TMD 1 is likely to be functionally irrelevant, because
SPP itself functions in the absence of its N-terminal domain
(16). The hydrophilic loop between TMD 6 and TMD 7 is
rather short and not well conserved, suggesting that it is
probably not suitable as a substrate receptor for GXGD-as-
partyl proteases. However, although the model that NCT
serves as the size-selecting substrate acceptor is very attrac-
tive, more recently it has been shown that a critical gluta-
mate thought to directly interact via a salt bridge with the
free N terminus of the shedded substrate could be
mutagenized to glutamine without significantly affecting
-secretase activity (28). Thus NCTmay not be the substrate
selecting subunit within the -secretase complex. Based on
the similar substrate requirements in terms of the length of
the ectodomain of -secretase and SPPL2b, one may argue
that PS itself could also harbor both a substrate binding site
and the size selector.
Although shedding greatly facilitates subsequent intramem-
brane proteolysis, it is by itself not sufficient for SPPL2b-medi-
ated endoproteolysis. This is reflected by the facts that (i)
FIGURE 5. The luminal JMD contributes to substrate recognition for
intramembrane proteolysis by SPPL2b. A, model of the chimeric Bri2/3E
variant. Only the luminal JMD of Bri2 is replaced by Bri3. B, Bri2/3E is less
efficiently processed by SPPL2b. Co-expression of Bri2/3E with SPPL2b or
SPPL2b D/A reveals reduced SPPL2b-dependent ICD generation compared
with co-expression with Bri2E. Chimeric Bri constructs were detected using
an anti-FLAG antibody. C, quantitative analysis of experiment shown in B. The
data represent the means  S.D. of nine independent experiments. The rel-
ative signal intensity of ICD compared with full-length protein was meas-
ured, normalized to calnexin, and set to 100% for Bri2E. SPPL2b-depend-
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FIGURE 6. The intracellular domain contributes to substrate recognition for
intramembrane proteolysis by SPPL2b. A, model of the chimeric Bri3/2/2 var-
iant. The ICD of Bri2 is replaced by that of Bri3. B, Bri3/2/2 is less efficiently pro-
cessed than Bri2. Co-expression of Bri3/2/2 or Bri2 with SPPL2b or the inactive
SPPL2b D/A variant shows reduced ICD generation for Bri3/2/2. Full-length Bri2
and Bri3/2/2 and their N-terminal processing products were detected using the
anti-FLAG antibody. The corresponding BRICHOS domains were visualized with
an anti-V5 antibody. The Bri3/2/2 NTF and the ICD show an altered running
behavior, probably caused by the difference in the ICD sequence. Analysis of
conditioned medium shows normal BRICHOS secretion and thus no influence on
the ectodomain shedding by the Bri3 ICD. C, quantitative analysis of experiment
shown in B. The data represent the means  S.D. of eight independent exper-
iments. The relative signal intensity of ICD compared with full-length pro-
tein and NTF was measured for both constructs, normalized to calnexin,
and set to 100% for Bri2. SPPL2b-dependent ICD generation is reduced to
37% for Bri3/2/2 (p  0.000009). D, model of the chimeric Bri2Ins Bri3 45–54
variant. 10 amino acids of the cytosolic juxtamembrane domain of Bri2
have been replaced by those of Bri3. E, Bri2Ins Bri3 45–54 is less efficiently
processed than Bri2. Co-expression of Bri2Ins Bri3 45–54 or Bri2 with SPPL2b or
the inactive SPPL2b D/A variant shows reduced ICD generation for Bri2Ins Bri3
45–54 comparable with Bri3/2/2. Full-length Bri2 and Bri2Ins Bri3 45–54, and their
N-terminal processing products were detected using the anti-FLAG antibody.
The corresponding BRICHOS domains were visualized with an anti-V5 anti-
body. Analysis of conditioned media shows normal BRICHOS secretion and
thus no influence on the ectodomain shedding by the Bri3 juxtamembrane
domain. F, quantitative analysis of experiment shown in E. The data represent
the means  S.D. of six independent experiments. The relative signal inten-
sity of ICD compared with full-length protein and NTF was measured for both
constructs, normalized to calnexin and set to 100% for Bri2. SPPL2b-depend-
ent ICD generation is reduced to 43% for Bri2Ins Bri3 45–54 (p  0.00154).
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Bri3E undergoes inefficient endoproteolysis and (ii) fusing
the ICD and TMD of Bri2 to the ectodomain of Bri3 allows at
least some intramembrane proteolysis, although shedding is
prevented.
The TMD provides additional substrate requirements that
are important for SPPL2b-mediated intramembrane proteoly-
sis. This may be in contrast to -secretase, where so far it
appears that numerous C-terminal fragments upon removal of
their ectodomains are substrates for the “membrane protea-
some function” of -secretase (37). On the other hand, pheny-
lalanine scanning of the TMD of the -amyloid precursor pro-
tein (APP) revealed at least some sequence specificity for
-secretase (38). This is also supported by a mutagenesis anal-
ysis of the GXGD domain within PS1, which suggests at least
some substrate specificity of PS1 itself (39). For SPP, it has been
described that the TMD requires helix-breaking residues to
allow intramembrane cleavage (29). However, the TMD of Bri3
also containsmultiple helix-braking residues but fails to be pro-
cessed efficiently by SPPL2b even upon removal of the Bri3
ectodomain. In line with this finding, intramembrane cleavage
still took place at least to some extent upon mutagenesis of the
helix-breaking residue within a SPP substrate (29). A very
recent study also suggests that amino acids not having a helix
breaking potential critically influence intramembrane proteol-
ysis by SPP (40). In addition to theTMD,we found that both the
luminal 23 amino acid of the JMD and the ICD also contribute
to the cleavability of Bri2. This is in line with the recent obser-
vation that the JMDofAPP is also required for efficient-secre-
tase-mediated proteolysis (41). Furthermore, Hemming et al.
(42) recently described substrate requirements for -secretase
substrates. Similar to the substrate requirements for SPPL2b,
they found that not only shedding of the ectodomain but also a
permissive transmembrane and cytoplasmic domain is
required. Moreover, in this study a very restricted substrate
selection was observed, which also challenges the idea that
-secretase functions like a membrane proteasome (37).
Interestingly, the very homologous Bri2 and Bri3 proteins
differ dramatically in terms of shedding. Whereas Bri2 is effi-
ciently shedded, Bri3 fails to be processed efficiently by a shed-
ding activity. This is specifically surprising, because sheddases
of the ADAM family exhibit no clear sequence specificity but
may rather recognize cleavage sites a short distance from the
plasma membrane (43). In that regard it is important to note
that both proteins reach the plasma membrane. Thus other
determinants such as dimerization and/or tertiary structure
may play a role. Indeed, -secretase, another shedding prote-
ase, preferentially processes dimerized APP (44–46).
In conclusion SPPL2b has the following substrate require-
ments: (i) a significantly truncated ectodomain, (ii) an appro-
priate TMD, (iii) a suitable JMD, and (iv) an appropriate
sequence in the ICD. Only a combination of all these determi-
nants allows efficient intramembrane proteolysis. In addition a
type 2 orientation of the substratemay be important, because at
least so far no type 1-oriented protein was identified as a
SPPL2b substrate.
Based on these findings and the similar substrate require-
ments of -secretase, we propose multiple substrate/enzyme
interactionswithin both juxtamembrane regions and theTMD.
This model may be supported by the recent findings that
-secretase protrudes into the extracellular and to some extent
also into the cytoplasmic space (11).
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